2 years ago

Mytos Secures $19 Million Series A Funding to Expand Automated Cell Production

  • Mytos, a London-based automated cell manufacturing company, has raised $19 million in Series A funding led by Buckley Ventures, with participation from IQ Capital and Wing VC

  • The company plans to use the funds to accelerate the manufacturing and distribution of its automated cell production system to more biotech and pharma companies

  • Mytos's platform automates the entire cell manufacturing process, ensuring cell production and yield while allowing remote monitoring of cell quality via digital data capture.

      • ProblemHealthcare

      "Manufacturing human cells for use in life-saving therapies is a complex and time-consuming process. It is often inefficient, unreliable, and requires specialized expertise."

      Solution

      "Mytos has developed an automated cell production system that enables life sciences companies to grow human cells with precision and efficiency. The platform automates the entire process, ensuring cell production and yield, while allowing remote monitoring of cell quality via digital data capture."

      Covered on